Petrelintide

Petrelintide (ZP8396) is an investigational long-acting amylin analog developed by Zealand Pharma in partnership with Roche, for once-weekly subcutaneous use in chronic weight management. Amylin — the pathway behind cagrilintide and pramlintide — promotes satiety through central pathways distinct from GLP-1. Petrelintide is engineered for chemical/physical stability with no fibrillation at neutral pH, enabling co-formulation with other peptides. It is not approved.

What is Petrelintide and why does an amylin-only approach matter?

Petrelintide pursues amylin agonism as a stand-alone lever — aiming to match GLP-1-level weight loss with better gastrointestinal tolerability, and potentially better lean-mass preservation. Petrelintide pursues amylin agonism as a standalone monotherapy — Zealand and Roche position it as a potential first-choice therapy for chronic weight management, aimed at people who want meaningful weight loss without incretin-class tolerability trade-offs. It is also being studied in combination with Roche's GLP-1/GIP agonist, positioning it as both a monotherapy and a combination partner.

What does the clinical evidence show?

In the Phase 2 ZUPREME-1 trial, once-weekly petrelintide produced up to ~10.7% mean weight loss at week 42 versus ~1.7% placebo, with placebo-like tolerability (no vomiting and no GI-related discontinuations at the maximally effective dose). That decision has been made: on April 29, 2026, Zealand Pharma and Roche announced they would advance petrelintide into Phase 3 trials for chronic weight management in adults with obesity or overweight with weight-related comorbidities, with initiation planned for the second half of 2026 — as of Zealand's August 13, 2026 half-year report, the registrational trials had not yet begun. The wider program also includes ZUPREME-2, a Phase 2b trial in overweight or obesity with type 2 diabetes (topline expected in the second half of 2026), and ZYNERGY, a planned Phase 2 trial combining petrelintide with the GLP-1/GIP agonist enicepatide (CT-388). The standout signal is tolerability rather than peak efficacy.

Sources: Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management, Zealand Pharma / Roche, via GlobeNewswire (company release; fetched via BioSpace syndication); Zealand Pharma Announces Financial Results for the First Half of 2026 (petrelintide program status), Zealand Pharma, via GlobeNewswire (company release) · Evidence level: phase 2 complete; Phase 3 decision pending — not approved

What are the known side effects and safety concerns?

Reported tolerability was notably favorable for the class, with GI adverse-event rates comparable to placebo at the effective dose; the full safety profile awaits Phase 3. These tolerability figures come from company-reported Phase 2 topline data; peer-reviewed safety reporting so far is limited to the published Phase 1 trials.

Source: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials, Brændholt Olsen M. et al. (optional, non-blocking: complete list), Diabetes Obes Metab, 2026 · Evidence level: phase 2

What is the regulatory status, and why is verification critical here?

Petrelintide is investigational and not approved by the FDA, EMA, or any other regulator as of August 2026 — no marketing application has been filed, and it is not commercially available anywhere. Any "petrelintide" sold through research-chemical vendors is not from Zealand/Roche and is unverified. Independent identity confirmation is the only meaningful check. See the legal status guide.

How does Peptigrity verify Petrelintide?

Peptigrity collects independent third-party Certificates of Analysis for petrelintide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. No independent petrelintide lab tests are on file yet (verified August 2026) — for an investigational compound with no reference product, an identity-confirmed, batch-matched COA is the only meaningful buyer signal. The trust score weights lab purity and reviews equally (50/50). See how to read lab results.

This section is for educational and informational purposes only and does not constitute medical advice. Petrelintide is not approved by the FDA or equivalent regulators for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.

Frequently asked questions